Budesonide/salmeterol
| Combination of | |
|---|---|
| Budesonide | Inhaled corticosteroid (ICS) |
| Salmeterol | Long-acting beta agonist (LABA) |
| Names | |
| Trade names | Labazenit |
| Other names | Budesonide/salmeterol xinafoate |
| Clinical data | |
| Main uses | Asthma[1] |
| Side effects | Throat inflammation, headache, voice changes, worsened asthma[1] |
| WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
| Routes of use | Inhaled[1] |
Budesonide/salmeterol (B/S), sold under the brand name Labazenit, is a combination medication used in the long-term treatment of asthma.[1] It main be used when an inhaled steroid alone is insufficient.[1] It is used by breathing the medication into the lungs.[1]
Side effects may include throat inflammation, headache, voice changes, and worsened asthma.[1] Serious side effects are uncommon.[1] It contains budesonide, an inhaled corticosteroid (ICS) and salmeterol, a long-acting beta agonist (LABA).[1]
It was denied approval in Europe in 2013.[2] It had not been approved for medical use in any country as of 2015.[1] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol.[3]
References
- 1 2 3 4 5 6 7 8 9 10 Popov, TA; De Niet, S; Vanderbist, F (February 2016). "Budesonide/salmeterol in fixed-dose combination for the treatment of asthma". Expert review of respiratory medicine. 10 (2): 113–25. doi:10.1586/17476348.2016.1133302. PMID 26677916.
- ↑ "Labazenit". European Medicines Agency. 17 September 2018. Archived from the original on 3 June 2023. Retrieved 23 August 2023.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.